ESMO 2019 | TNBC treatment: platinum-based therapy and PARP inhibition

Name: TNBC treatment: platinum-based therapy and PARP inhibition
Uploaded: 2019-09-27T00:00:00Z
Duration: 58 s
Description: Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, talks about BRCA mutations in triple-negative breast cancer (TNBC) and the promising response to cytotoxic platinum-based chemotherapy and PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Véronique Dieras • 27 Sep 2019

ESMO 2019

Breast Cancer

Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, talks about BRCA mutations in triple-negative breast cancer (TNBC) and the promising response to cytotoxic platinum-based chemotherapy and PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.